Personalized Cancer Vaccines Market 2024

The personalized cancer vaccines market size has grown strongly in recent years. It will grow from $227.31 billion in 2023 to $242.29 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth observed during the historic period can be attributed to several factors, including advancements in genomic research, the development of targeted therapies, a deeper understanding of tumor immunology, progress in vaccine technology, and an increase in clinical trial data demonstrating efficacy.

The personalized cancer vaccines market size is expected to see strong growth in the next few years. It will grow to $315.16 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth during the forecast period can be attributed to several factors, including advancements in precision medicine, increased funding for cancer research, a rising prevalence of cancer cases, improvements in genetic sequencing technologies, and a growing interest in personalized treatment options. Key trends expected in this period include the integration of artificial intelligence in vaccine design, advancements in multi-antigen and neoantigen-based vaccines, a greater use of liquid biopsies for tumor monitoring, the expansion of combination therapies, and a heightened focus on personalized treatment regimens.

The rising incidence of cancer is projected to drive the growth of the personalized cancer vaccine market in the coming years. Cancer encompasses a range of diseases characterized by abnormal cell growth that can metastasize to other areas of the body. This increase in cancer prevalence is attributed to factors such as aging populations, changes in lifestyle, exposure to environmental pollutants, genetic predispositions, and advancements in diagnostic methods. Personalized cancer vaccines aim to combat this rising prevalence by specifically targeting tumor antigens that are unique to each patient, thereby enhancing the immune system's ability to identify and eliminate cancer cells. For example, a report from the Australian Institute of Health and Welfare in July 2024 indicated that cancer diagnoses in Australia rose from 160,570 cases in 2022 to 164,694 in 2023, showcasing a significant increase. Thus, the growing prevalence of cancer is propelling the expansion of the personalized cancer vaccine market.

Key players in the personalized cancer vaccine market are concentrating on developing innovative therapeutic options, such as personalized immunotherapy, to improve precision in addressing specific cancer mutations. These personalized immunotherapy solutions are tailored treatments that leverage a patient’s unique genetic and tumor profiles to enhance immune responses against cancer. For instance, in August 2024, UCLA Health, a healthcare organization based in the U.S., initiated a groundbreaking clinical trial to assess the safety and efficacy of a cancer vaccine. This vaccine, developed at UCLA, employs a personalized immunotherapy approach to target the H3 G34 mutation associated with diffuse hemispheric gliomas, a highly aggressive brain tumor commonly found in adolescents and young adults. The method utilizes dendritic cells to activate the immune system specifically against the RNA disruptions caused by this mutation. This strategy, which has shown potential in treating other cancers, aims to improve outcomes for patients who often have limited treatment options and short survival rates.

In March 2022, NEC OncoImmunity AS, a biotechnology firm from Norway, acquired the neoantigen program assets from VAXIMM GmbH for an undisclosed sum. This acquisition is intended to bolster NEC OncoImmunity's development of neoantigen cancer vaccines, including patents and existing collaboration agreements. This strategic move will enhance NEC OncoImmunity's capacity to advance personalized cancer immunotherapies, building on their prior collaboration with VAXIMM. VAXIMM GmbH is a biopharmaceutical company based in Germany that specializes in the development of personalized cancer vaccines.

Major companies operating in the personalized cancer vaccines market are Merck & Co Inc, GlaxoSmithKline Plc, NEC Corporation, Moderna Inc, Catalent Inc, UCLA Health, Genetech Inc, NHS England, CureVac AG, Personalis Inc, Achilles Therapeutics Plc, Healio, Moffitt Corporation, BioPharma APAC, Celebrity Angels, EpiVax Therapeutics Inc., Evaxion Biotech AS, Geneos Therapeutics Inc, IFL Sciense, ISA Pharmaceuticals BV, Oxford Global, Kintara Therapeutics, VAXIMM Gmbh.

North America was the largest region in the personalized cancer vaccines market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the personalized cancer vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Personalized cancer vaccines are treatments specifically designed to match an individual’s unique tumor profile, with the goal of stimulating the immune system to target and eliminate cancer cells. These vaccines enhance the body’s ability to recognize and combat specific cancer types, potentially improving treatment effectiveness and reducing the likelihood of recurrence.

The main categories of personalized cancer vaccines include preventive cancer vaccines and therapeutic cancer vaccines. Preventive cancer vaccines aim to protect against infections or conditions that could lead to cancer. These vaccines can be utilized for various cancer types, including lung cancer, breast cancer, colorectal cancer, leukemia, prostate cancer, cervical cancer, and glioblastoma. They operate through different mechanisms of action, such as targeting tumor-associated antigens (TAAs), tumor-specific antigens (TSAs), and addressing somatic mutations in cancer pharmacogenomics, among other factors. They are administered via various routes, including injectables, and are used in a range of settings, such as hospitals and clinics.

The personalized cancer vaccines market research report is one of a series of new reports that provides personalized cancer vaccines market statistics, including personalized cancer vaccines industry global market size, regional shares, competitors with a personalized cancer vaccines market share, detailed personalized cancer vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the personalized cancer vaccines industry. This personalized cancer vaccines market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The personalized cancer vaccines market consists of sales of patient-specific vaccines, neoantigen-based therapies, dendritic cell-based vaccines and peptide-based immunotherapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.